Veklury significantly reduced risk of hospitalization in high-risk patients with COVID-19 – Gilead Sciences
Gilead Sciences, Inc. announced positive results from a Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury(remdesivir) for intravenous… read more.